Ann Dermatol.  2017 Apr;29(2):260-262. 10.5021/ad.2017.29.2.260.

Treatment of Recalcitrant Pyoderma Gangrenosum with Ulcerative Colitis by Adalimumab Injection

• Lee JH
• Chang IK
• Lee HE
• Im M
• Seo YJ
• Lee JH
• Lee Y

• KMID: 2394864
• DOI: http://doi.org/10.5021/ad.2017.29.2.260

Abstract

No abstract available.

MeSH Terms

Adalimumab*
Colitis, Ulcerative*
Pyoderma Gangrenosum*
Pyoderma*
Ulcer*
Adalimumab

Figure

• 

  Fig. 1 (A) Initial cutaneous lesion. Five-year history of erythematous, recurrent, painful nodules and ulcers on the left lower leg. (B) Despite several months of treatment, there was only a minimal therapeutic effect. (C) After the 13th injection of etanercept, the pain and ulceration dramatically improved.

• 

  Fig. 2 (A) After 1 year of using etanercept, the skin lesion gradually worsened. Mild tenderness and a small ulceration recurred. (B) After the 8th injection of adalimumab, a clinically complete remission was obtained. (C) One year after the last (9th) injection of adalimumab, complete healing was still being maintained.

Reference

1. Powell FC, Hackett BC, Wallach D. Pyoderma gangrenosum. In : Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick's dermatology in general medicine. 8th ed. New York: McGraw-Hill;2012. p. 371–379.

2. Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol. 2005; 152:1059–1061.

3. Reguiaï Z, Grange F. The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease. Am J Clin Dermatol. 2007; 8:67–77.

4. Levin EC, Gupta R, Brown G, Malakouti M, Koo J. Biologic fatigue in psoriasis. J Dermatolog Treat. 2014; 25:78–82.

5. Cozzani E, Burlando M, Parodi A. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study. G Ital Dermatol Venereol. 2013; 148:171–174.